Clin Exp Vaccine Res.  2014 Jan;3(1):91-99. 10.7774/cevr.2014.3.1.91.

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children

Affiliations
  • 1Department of Pediatrics, Kyung Hee University Hospital, Kung Hee University School of Medicine, Seoul, Korea. sunghocha@khu.ac.kr
  • 2Department of Pediatrics, Hangang Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Korea.
  • 3Department of Pediatrics, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
  • 4Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
  • 5Department of Statistics, GlaxoSmithKline Biologicals, Wavre, Belgium.
  • 6Department of Pediatrics, Yonsei University Wonju College of Medicine, Wonju, Korea.
  • 7Clinical Development, MMR/V Vaccines, Global Vaccines Development, GlaxoSmithKline Biologicals-Philadelphia, King of Prussia, PA, USA.

Abstract

PURPOSE
This study (NCT00751348) evaluated the immunogenicity and safety of a combined measles-mumps-rubella-varicella (MMRV) vaccine compared to co-administration of measles-mumps-rubella and varicella (MMR+V) vaccines in Korean children during their second year of life.
MATERIALS AND METHODS
Healthy children aged 11-24 months received one dose of MMRV or MMR+V. Antibody titers against measles, mumps and rubella were measured using enzyme-linked immunosorbent assay and against varicella using an immunofluorescence assay. Parents/guardians recorded adverse events in diary cards for up to 43 days post-vaccination. The primary objective was to demonstrate non-inferiority of MMRV to MMR+V for all antigens in terms of seroconversion rates (SCRs), defined as a group difference with a lower limit of the 95% confidence interval (CI)>-10%.
RESULTS
Of 474 subjects enrolled, 458 (MMRV, 301; MMR+V, 157) were included in the according-to-protocol cohort. For measles (98.0% vs. 99.4%), rubella (99.7% vs. 100%) and varicella (98.9% vs. 100%) SCRs, the lower limits of the 95% CIs for group differences were greater than -10%; however, for mumps SCRs (88.8% vs. 94.2%), it was -10.40%. The primary objective of non-inferiority in mumps SCRs was therefore not met, although the observed group difference in a post-hoc analysis of anti-mumps antibodies using a plaque reduction neutralization assay was 0.39% with a 95% CI lower limit of -4.03%. Adverse events occurred at comparable frequencies for both groups, except for more frequent fever in MMRV recipients.
CONCLUSION
Based on the pre-specified non-inferiority criterion, SCRs of the MMRV vaccine were non-inferior to that elicited by MMR+V vaccines for all antigens except mumps.

Keyword

Immunogenicity; Safety; Plaque reduction assay; Measles-mumps-rubella-varicella vaccine; Korea

MeSH Terms

Antibodies
Chickenpox
Child*
Cohort Studies
Enzyme-Linked Immunosorbent Assay
Fever
Fluorescent Antibody Technique
Humans
Korea
Measles
Mumps
Rubella
Vaccines
Antibodies
Vaccines

Figure

  • Fig. 1 Study profile. MMRV, measles-mumps-rubella-varicella; MMR+V, measles-mumps-rubella and varicella vaccines administered concomitantly; ATP, according-to-protocol.

  • Fig. 2 Reverse cumulative curve of anti-mumps antibody concentrations (ATP cohort). MMR+V, measles-mumps-rubella and varicella vaccines administered concomitantly; MMRV, measles-mumps-rubella-varicella; ATP, according-to-protocol.

  • Fig. 3 Prevalence of fever (any intensity) during the follow-up period (day 0-42). MMR+V, measles-mumps-rubella and varicella vaccines administered concomitantly; MMRV, measles-mumps-rubella-varicella.


Reference

1. Measles vaccines: WHO position paper. Wkly Epidemiol Rec. 2009; 84:349–360.
2. Mumps virus vaccines. Wkly Epidemiol Rec. 2007; 82:51–60.
3. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2011; 86:301–316.
4. Atkinson W, Wolfe S, Hamborsky J. Epidemiology and prevention of vaccine-preventable diseases. The Pink Book: course textbook. 12th ed. Washington, DC: Public Health Foundation;2011.
5. Lee H, Kim HW, Cho HK, Park EA, Choi KM, Kim KH. Reappraisal of MMR vaccines currently used in Korea. Pediatr Int. 2011; 53:374–380.
Article
6. Centers for Disease Control and Prevention (CDC). Elimination of measles: South Korea, 2001-2006. MMWR Morb Mortal Wkly Rep. 2007; 56:304–307.
7. Choe YJ, Lee ST, Song KM, Cho H, Bae GR, Lee JK. Surveillance and control of rubella in the Republic of Korea from 2001 to 2009: the necessity for enhanced surveillance to monitor congenital rubella syndrome. Osong Public Health Res Perspect. 2010; 1:23–28.
Article
8. Choi WS, Noh JY, Huh JY, et al. Seroprevalence of varicella-zoster virus in Korea. J Med Virol. 2010; 82:2123–2126.
Article
9. Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine. 2009; 27:6504–6511.
Article
10. Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56:1–40.
11. Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J. 2007; 26:632–638.
Article
12. Stück B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol. 2002; 20:113–120.
13. Nolan T, McIntyre P, Roberton D, Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine. 2002; 21:281–289.
Article
14. Goh P, Lim FS, Han HH, Willems P. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection. 2007; 35:326–333.
Article
15. Rümke HC, Loch HP, Hoppenbrouwers K, et al. Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine. 2011; 29:3842–3849.
Article
16. Schuster V, Otto W, Maurer L, et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008; 27:724–730.
Article
17. Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J. 2007; 26:153–158.
Article
18. Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006; 25:12–18.
Article
19. Mauldin J, Carbone K, Hsu H, Yolken R, Rubin S. Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays. J Clin Microbiol. 2005; 43:4847–4851.
Article
20. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika. 1934; 26:404–413.
Article
21. Knuf M, Faber J, Barth I, Habermehl P. A combination vaccine against measles, mumps, rubella and varicella. Drugs Today (Barc). 2008; 44:279–292.
Article
22. Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005; 24:665–669.
Article
23. Gillet Y, Steri GC, Behre U, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009; 27:446–453.
Article
24. Rentier B, Gershon AA, European Working. Consensus: varicella vaccination of healthy children: a challenge for Europe. Pediatr Infect Dis J. 2004; 23:379–389.
25. Marcy SM. Pediatric combination vaccines: their impact on patients, providers, managed care organizations, and manufacturers. Am J Manag Care. 2003; 9:314–320.
26. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003; 9:1 Suppl. S6–S12.
27. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009; 27:4656–4661.
Article
28. Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010; 126:e1–e8.
Article
29. Committee on Infectious Diseases. Policy statement: prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics. 2011; 128:630–632.
Full Text Links
  • CEVR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr